Therapeutic treatment of New Zealand mouse disease by a limited number of anti-idiotypic antibodies conjugated with neocarzinostatin.

N Harata; T Sasaki; H Osaki; T Saito; S Shibata; T Muryoi; O Takai; K Yoshinaga

doi:10.1172/JCI114773

Second Department of Internal Medicine, Tohoku University School of Medicine, Sendai, Japan.

Find articles by Harata, N. in: PubMed | Google Scholar

Second Department of Internal Medicine, Tohoku University School of Medicine, Sendai, Japan.

Find articles by Sasaki, T. in: PubMed | Google Scholar

Second Department of Internal Medicine, Tohoku University School of Medicine, Sendai, Japan.

Find articles by Osaki, H. in: PubMed | Google Scholar

Second Department of Internal Medicine, Tohoku University School of Medicine, Sendai, Japan.

Find articles by Saito, T. in: PubMed | Google Scholar

Second Department of Internal Medicine, Tohoku University School of Medicine, Sendai, Japan.

Find articles by Shibata, S. in: PubMed | Google Scholar

Second Department of Internal Medicine, Tohoku University School of Medicine, Sendai, Japan.

Find articles by Muryoi, T. in: PubMed | Google Scholar

Second Department of Internal Medicine, Tohoku University School of Medicine, Sendai, Japan.

Find articles by Takai, O. in: PubMed | Google Scholar

Second Department of Internal Medicine, Tohoku University School of Medicine, Sendai, Japan.

Find articles by Yoshinaga, K. in: PubMed | Google Scholar

Published in Volume 86, Issue 3 on September 1, 1990
J Clin Invest. 1990;86(3):769–776. https://doi.org/10.1172/JCI114773.
© 1990 The American Society for Clinical Investigation

Published September 1, 1990 - Version history

-81 and NE-1 idiotypes (Id) of human nephritogenic anti-DNA antibodies are interspecies Id expressed also in NZB/W F1 mice. We tried to manipulate the synthesis of spontaneously occurring anti-DNA antibody using monoclonal anti-Id antibodies (D1E2 and 1F5) conjugated with a cytotoxic agent, neocarzinostatin (NCS). In vivo administration of anti-Id antibodies conjugated with NCS brought about an improvement in the survival rate of female NZB/W F1 mice. It also caused a retardation of development of lupus nephritis and decreased the numbers of anti-DNA-producing cells. The suppression of anti-DNA antibody synthesis was specific and Id-mediated. The results indicate that the use of a limited number of anti-Id antibodies in combination with a cytotoxic agent may be applicable therapeutically to autoimmune diseases.

Images.

Version 1 (September 1, 1990): No description

Therapeutic treatment of New Zealand mouse disease by a limited number of anti-idiotypic antibodies conjugated with neocarzinostatin.

N Harata, T Sasaki, H Osaki, T Saito, S Shibata, T Muryoi, O Takai, and K Yoshinaga

Article tools

Metrics

Go to

Therapeutic treatment of New Zealand mouse disease by a limited number of anti-idiotypic antibodies conjugated with neocarzinostatin.

N Harata, T Sasaki, H Osaki, T Saito, S Shibata, T Muryoi, O Takai, and K Yoshinaga

Article tools

Metrics

Go to

Sign up for email alerts